Insight

Goutham Sunny/LinkedIn

Jul 5, 2025, 16:06

Goutham Sunny: VISION Trial and Beyond

Goutham Sunny, Assistant Professor at The Gujarat Cancer and Research Institute, shared a post on X:

“Tepotinib in METex14 Skipping NSCLC – VISION Trial and Beyond

Background:

VISION Trial – Key Highlights:

Robust, durable efficacy in METex14+ NSCLC
Particularly effective in first-line setting
Consistent benefit across subgroups: Elderly and young, Asian patients, With/without brain metastases
Real-world evidence (RWE) supports trial data
Long-term safety manageable with preserved HRQOL (Health-Related Quality of Life)
Approved globally: Japan (2020), USA (2021 accelerated, 2024 full),

Mechanism:

Selective MET inhibition blocks MET-driven signaling → halts tumor growth and spread

Clinical Use Insights:

Pros:

Cons:

Significance:

Tepotinib represents a major step forward for a previously underserved NSCLC subset
Supports biomarker-driven precision oncology
VISION + RWE help inform optimal treatment sequencing and real-world applicability”

Title: Tepotinib in patients with MET exon 14 skipping non-small cell lung cancer

Authors: Paul K. Paik, Wade T. Iams, Hatim Husain, Richard M. O’Hara Jr., Emmanuel Adewusi, Xiuning Li

You can read the Full Article on Cancer Treatment Reviews

Goutham Sunny: VISION Trial and Beyond